[en] The introduction of biologics, such as benralizumab (an anti-IL-5 receptor α humanised monoclonal antibody), has made remission a feasible goal for patients with severe eosinophilic asthma (SEA). However, there are remaining research gaps and no clear consensus on the definition of remission. We consolidated post hoc remission data from clinical trials and real-world studies of benralizumab in patients with SEA to gather insights on: testing different definitions; predictors of remission; the effect of comorbidities on achieving remission; remission and background medication reduction; long-term remission patterns with benralizumab; and remission in a real-life setting. In the SIROCCO and CALIMA Phase 3 randomised studies, patients with remission had higher baseline median blood eosinophil counts, were more likely to have a FEV(1) of ≥ 65% predicted, had fewer exacerbations within 12 months and had lower mean ACQ-6 scores. Compared with the overall population, patients with a history of nasal polyps were also more likely to achieve remission with benralizumab. Analyses of the BORA and MELTEMI extension studies showed that in the longer term, once remission is achieved with benralizumab, patients are likely to remain in remission with continued treatment. In the open-label, single-arm ANDHI-In Practice and PONENTE studies, patients achieving remission had a shorter median time since asthma diagnosis, higher median age at asthma onset and lower median ACQ-6 scores. The SHAMAL study and the Phase 3b ANDHI-In Practice substudy demonstrate that remission is maintained with benralizumab even when patients reduce their background medication. Finally, the XALOC-1 real-world study highlights how patients with lower BMI are more likely to achieve remission with benralizumab. These findings demonstrate that achieving remission in patients with SEA is feasible with benralizumab and, in turn, inform future directions for research and treatment that includes a promising shift towards a new era of treat-to-target. This manuscript was supported by AstraZeneca, the manufacturer of benralizumab.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Lommatzsch, Marek ; Department of Pneumology, University of Rostock, Rostock, Germany.
Jackson, David J ; Guy's Severe Asthma Centre, Guy's & St Thomas NHS Trust, London, UK. ; School of Immunology & Microbial Sciences, King's College London, London, UK.
Menzies-Gow, Andrew ; BioPharmaceutials Medical, AstraZeneca, Cambridge, UK.
K. F. Chung, S. E. Wenzel, J. L. Brozek, et al., “International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma,” European Respiratory Journal 43, no. 2 (2014): 343–373.
S. C. Dharmage, J. L. Perret, and A. Custovic, “Epidemiology of Asthma in Children and Adults,” Frontiers in Pediatrics 18, no. 7 (2019): 246.
D. J. Jackson, J. Busby, P. E. Pfeffer, et al., “Characterisation of Patients With Severe Asthma in the UK Severe Asthma Registry in the Biologic Era,” Thorax 76, no. 3 (2021): 220–227.
E. Wang, M. E. Wechsler, T. N. Tran, et al., “Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry,” Chest 157, no. 4 (2020): 790–804, https://doi.org/10.1016/j.chest.2019.10.053.
L. G. Heaney, L. Perez de Llano, M. Al-Ahmad, et al., “Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort,” Chest 160, no. 3 (2021): 814–830.
6. M. Lommatzsch, P. Nair, and J. C. Virchow, “Normal Blood Eosinophil Counts in Humans,” Respiration 103, no. 4 (2024): 214–216.
S. Hartl, M. K. Breyer, O. C. Burghuber, et al., “Blood Eosinophil Count in the General Population: Typical Values and Potential Confounders,” European Respiratory Journal 55, no. 5 (2020): 1901874.
G. Garcia, C. Taillé, P. Laveneziana, A. Bourdin, P. Chanez, and M. Humbert, “Anti-Interleukin-5 Therapy in Severe Asthma,” European Respiratory Review 22, no. 129 (2013): 251–257.
R. Kolbeck, A. Kozhich, M. Koike, et al., “MEDI-563, a Humanized Anti-IL-5 Receptor Alpha mAb With Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity Function,” Journal of Allergy and Clinical Immunology 125, no. 6 (2010): 1344, e2–1353.
S. Hansen, M. Baastrup Søndergaard, A. von Bülow, et al., “Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies,” Chest 165, no. 2 (2024): 253–266.
A. Menzies-Gow, M. Bafadhel, W. W. Busse, et al., “An Expert Consensus Framework for Asthma Remission as a Treatment Goal,” Journal of Allergy and Clinical Immunology 145, no. 3 (2020): 757–765.
M. Lommatzsch, G. G. Brusselle, G. W. Canonica, et al., “Disease-Modifying Anti-Asthmatic Drugs,” Lancet 399, no. 10335 (2022): 1664–1668.
13. D. T. Felson, J. S. Smolen, G. Wells, et al., “American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials,” Annals of the Rheumatic Diseases 70, no. 3 (2011): 404–413.
S. Ajeganova and T. Huizinga, “Sustained remission in rheumatoid arthritis: Latest evidence and clinical considerations,” Ther Adv Musculoskelet Dis 9, no. 10 (2017): 249–262.
W. Sandborn, J.-F. Colombel, M. Yang, R. Thakkar, P. Mulani, and J. Chao, “Sustained Clinical Remission of Ulcerative Colitis Is Associated With Greater Improvements in Quality of Life, Work Productivity and Activity,” American Journal of Gastroenterology 106 (2011): S456.
M. Lommatzsch and J. C. Virchow, “Asthma Remission: A Call for a Globally Standardized Definition,” Lancet Respiratory Medicine 13, no. 1 (2025): 2–3.
L. M. van den Toorn, S. E. Overbeek, J. C. de Jongste, K. Leman, H. C. Hoogsteden, and J. B. Prins, “Airway Inflammation Is Present During Clinical Remission of Atopic Asthma,” American Journal of Respiratory and Critical Care Medicine 164, no. 11 (2001): 2107–2113.
J. W. Upham and A. L. James, “Remission of Asthma: The Next Therapeutic Frontier?,” Pharmacology & Therapeutics 130, no. 1 (2011): 38–45.
M. Lommatzsch, “Remission in Asthma,” Current Opinion in Pulmonary Medicine 30, no. 3 (2024 2024/03/05): 325–329.
M. Blaiss, J. Oppenheimer, M. Corbett, et al., “Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment,” Ann Allergy Asthma Immunol 131, no. 6 (2023): 782–785.
M. Lommatzsch, R. Buhl, G. W. Canonica, et al., “Pioneering a Paradigm Shift in Asthma Management: Remission as a Treatment Goal,” Lancet Respiratory Medicine 12, no. 2 (2024): 96–99.
M. Lommatzsch, C. P. Criée, C. C. M. de Jong, et al., “Diagnosis and Treatment of Asthma: A Guideline for Respiratory Specialists 2023 [in German],” Pneumologie 77, no. 8 (2023): 461–543.
V. Plaza Moral, I. Alobid, C. Álvarez Rodríguez, et al., “GEMA 5.3. Spanish Guideline on the Management of Asthma,” Open Respir Arch 5, no. 4 (2023): 100277.
Global Initiative for Asthma. “Global Strategy for Asthma Management and Prevention (2024 Update),” https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf.
W. W. Busse, G. Chupp, T. Corbridge, A. Stach-Klysh, and J. Oppenheimer, “Targeting Asthma Remission as the Next Therapeutic Step Toward Improving Disease Control,” Journal of Allergy and Clinical Immunology: In Practice 14, no. 4 (2024 2024/02/07): 894–903.
D. J. Jackson, L. G. Heaney, M. Humbert, et al., “Reduction of Daily Maintenance Inhaled Corticosteroids in Patients With Severe Eosinophilic Asthma Treated With Benralizumab (SHAMAL): A Randomised, Multicentre, Open-Label, Phase 4 Study,” Lancet 403, no. 10423 (2024): 271–281.
E. R. Bleecker, J. M. FitzGerald, P. Chanez, et al., “Efficacy and Safety of Benralizumab for Patients With Severe Asthma Uncontrolled With High-Dosage Inhaled Corticosteroids and Long-Acting β,” Lancet 388, no. 10056 (2016): 2115–2127.
J. M. FitzGerald, E. R. Bleecker, P. Nair, et al., “Benralizumab, an Anti-Interleukin-5 Receptor α Monoclonal Antibody, as Add-On Treatment for Patients With Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial,” Lancet 388, no. 10056 (2016): 2128–2141.
W. W. Busse, E. R. Bleecker, J. M. FitzGerald, et al., “Long-Term Safety and Efficacy of Benralizumab in Patients With Severe, Uncontrolled Asthma: 1-Year Results From the BORA Phase 3 Extension Trial,” Lancet Respiratory Medicine 7, no. 1 (2019): 46–59, https://doi.org/10.1016/S2213-2600(18)30406-5.
S. Korn, A. Bourdin, G. Chupp, et al., “Integrated Safety and Efficacy Among Patients Receiving Benralizumab for up to 5 Years,” Journal of Allergy and Clinical Immunology: In Practice 9, no. 12 (2021): 4381–4392.
R. Louis, T. W. Harrison, P. Chanez, et al., “Severe Asthma Standard-Of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy,” Journal of Allergy and Clinical Immunology: In Practice 11, no. 6 (2023): 1759–1770.
A. Menzies-Gow, M. Gurnell, L. G. Heaney, et al., “Oral Corticosteroid Elimination via a Personalised Reduction Algorithm in Adults With Severe, Eosinophilic Asthma Treated With Benralizumab (PONENTE): A Multicentre, Open-Label, Single-Arm Study,” Lancet Respiratory Medicine 10, no. 1 (2022): 47–58.
D. J. Jackson, G. Pelaia, B. Emmanuel, et al., “Benralizumab in Severe Eosinophilic Asthma by Previous Biologic Use and Key Clinical Subgroups: Real-World XALOC-1 Programme,” European Respiratory Journal 64, no. 1 (2024): 2301521.
D. J. Jackson, G. Pelaia, A. Padilla-Galo, et al., “Clinical Remission in Patients With Severe Eosinophilic Asthma With Benralizumab According to Body Mass Index Status in an Integrated Analysis of the Real-World XALOC-1 Study,” Allergy 78, no. S112 (2023): 485–486.
D. J. Jackson, H. Burhan, H. Rupani, et al., “Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two-Year Real-World Data With Benralizumab,” Clinical and Experimental Allergy 54 (2024): 734–746.
D. Carstens, D. Ojeranti, Y. Chung, K. Chan, and N. Dhopeshwarkar, “Heterogeneous Characteristics of Severe Asthma Patients Initiating Benralizumab in a Real-World Setting: The ZEPHYR-4 Study,” Annals of Allergy, Asthma & Immunology 131, no. 5 (2023): S51–S52.
M. Lommatzsch, A. Shavit, A. Bourdin, et al., “Durability of Benralizumab-Induced Remission in Severe Asthma: An Analysis of the BORA Study,” European Respiratory Journal 62, no. 67 (2023): OA1420.
A. Khan, S. Kamat, L. Eckert, et al., “Impact of Baseline Lung Function on Future Exacerbations in Patients With Moderate-To-Severe Asthma,” Annals of Allergy, Asthma & Immunology 121, no. 5 (2018): S44, https://doi.org/10.1016/j.anai.2018.09.140.
D. Thomas, V. M. McDonald, I. D. Pavord, and P. G. Gibson, “Asthma Remission: What Is It and How Can It Be Achieved?,” European Respiratory Journal 60, no. 5 (2022): 2102583.
D. H. Solomon, A. Bitton, J. N. Katz, H. Radner, E. M. Brown, and L. Fraenkel, “Review: Treat to Target in Rheumatoid Arthritis: Fact, Fiction, or Hypothesis? Arthritis,” Rheumatol 66, no. 4 (2014): 775–782.
L. J. Nannini, “Treat to Target Approach for Asthma,” Journal of Asthma 57, no. 6 (2020): 687–690.
N. Pierre, S. Vieujean, L. Peyrin-Biroulet, M. A. Meuwis, and E. Louis, “Defining Biological Remission in Crohn's Disease: Interest, Challenges and Future Directions,” Journal of Crohn's & Colitis 17, no. 10 (2023): 1698–1702.
